According to a recent LinkedIn post from Visby Medical, the company is working with telehealth provider Wisp to offer what is described as the first at-home PCR sexually transmitted infection test directed at women. The post indicates the Visby device is designed to provide lab-quality results in roughly 30 minutes in a home setting.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post also notes that patients with positive results can connect to Wisp for telehealth consultations and, when appropriate, immediate treatment. This integrated diagnostic-to-care pathway suggests a strategy to reduce friction between testing and therapy, potentially increasing adoption and positioning Visby Medical within the broader telehealth and women’s health markets.
For investors, the collaboration appears to underscore Visby Medical’s focus on point-of-care PCR technology and direct-to-consumer channels. If scaled successfully, such a model could expand recurring test utilization, strengthen partnerships in digital health, and support revenue growth while enhancing the company’s competitive profile in diagnostics and telehealth-enabled care.